サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1129254

マルチプレックス診断の世界市場-2022-2029

Global Multiplexed Diagnostics Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
マルチプレックス診断の世界市場-2022-2029
出版日: 2022年09月29日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

様々なアプリケーションに対応したマルチプレックス診断の進歩が市場成長の原動力となることが予想されます。

進行性疾患の早期発見と監視のために、正確で信頼性が高く経済的な、臨床的に重要な免疫センサーが求められています。マルチプレックス・センシングは、次世代の診断法として期待されている手法です。この方法では、多数のバイオマーカーを同時に検出・定量することができ、再現性と信頼性が大幅に向上します。また、バイオマーカーごとに別々の検査を行うよりも、試料量が少なく、平均分析時間が短くなります。例えば、最も頻繁に議論されている多重化技術の1つは、検出の干渉を最小限に抑え、ほとんどの測定技術と互換性があるため、空間多重化です。電気的測定のためのセンシング機構として、電界効果トランジスタが頻繁に使用される（FET）。各トランジスタは導電性または半導体性のチャネルで構成されており、特定の抗体によってこのチャネルが変化しています。抗原が結合するとドレイン・ソース間の電流が調整され、そこから標的バイオマーカーの濃度が算出されます。以上のことから、予測期間において、市場の牽引役となることが期待されます。

抑制要因

抑制要因：マルチプレックス診断アッセイに関連する高コスト、熟練した専門家の不足、マルチプレックス診断アッセイ診断テストを従来の診断テストと比較すると、民間および政府のプレーヤー間で償還規制に関する明確性が欠如しています。したがって、上記の記述から、予測期間中に市場が阻害されることが予想されます。

産業分析

マルチプレックス診断市場は、ポーターの5つの力、サプライチェーン分析、償還シナリオ、製品イノベーション、価格分析など、様々な業界要因に基づく市場の詳細な分析を提供します。

COVID-19の影響分析

COVID-19のパンデミックは、ヘルスケアシステムと市場に中程度の影響を及ぼしています。SARS-CoV-2感染を実用的かつ迅速に検出するための迅速な分子検査は、現在のパンデミックを管理し、さらなる発生を防止するのに役立つ課題です。凍結乾燥LAMP試薬は、SARS-CoV-2を迅速かつ高感度に検出するために設計されたマルチプレックスおよび比色RT-LAMPアッセイに使用されています。ウイルスのゲノムワイド解析によって見出された一連の遺伝子ターゲットが、LAMPプライマーの作成のきっかけとなりました。最も優れた特徴を持つプライマーセットを用いて、マルチプレックスRT-LAMPアッセイを作製しました。分析バリデーションの一環として、検出限界（LoD）、アッセイ内およびアッセイ間の精度、他の呼吸器系病原体との交差反応性も評価されました。そのため、マルチプレックス診断アッセイに対する需要が高まっています。

一方、パンデミックはサプライチェーンとプロセスを中断させる。多くの企業は、製品の入手可能性を確保し、サプライチェーンを保護するために、他の地域へと変化していくでしょう。したがって、上記の記述から、市場は影響を受けましたが、経済活動の再開に伴い、急速に牽引されると予想されます。

本レポートでは、45以上の市場データ表、40以上の図表、180ページにわたる情報を提供しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場影響要因
    • 促進要因
      • 様々なアプリケーションに対応したマルチプレックス診断の進歩が市場成長の原動力になると予想されます。
    • 抑制要因
      • 多項目診断に伴う高コストが市場成長を阻害します。
    • 機会
    • 影響分析

第5章 産業分析

  • サプライチェーン分析
  • 価格設定分析
  • アンメットニーズ分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 製品タイプ別

  • 試薬・消耗品
  • 器具
  • その他

第8章 技術別

  • 低密度マルチプレックスアッセイ
  • 中濃度マルチプレックスアッセイ
  • 高密度マルチプレックスアッセイ
  • 超高密度マルチプレックスアッセイ
  • 次世代シーケンシングアッセイ
  • その他

第9章 アプリケーション別

  • 疾患診断
  • 分子生物学的診断
  • 医薬品開発
  • その他

第10章 エンドユーザー別

  • 病院
  • 臨床検査機関
  • 学術・研究機関
  • 診断センター
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 企業プロファイル

  • Luminex Corporation
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories, Inc.
  • Qiagen N.V.
  • Siemens Healthineers
  • Agilent technologies
  • BioMerieux SA
  • F.Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Illumina, Inc.

第14章 マルチプレックス診断の世界市場-DataM

目次
Product Code: DMCD5801

Market Overview

The Multiplexed Diagnostics Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Biological samples are analyzed using multiplexed diagnostics, which can finish a screening procedure in a single pass. Multiplexed diagnostic assays identify and classify various illnesses and infections, including cancer, autoimmune disorders, allergies, and cardiovascular diseases. Early detection can reduce the risk factors linked to chronic illnesses or infections and aid in effective treatment administration. Multiplexed diagnostic assays have benefits like time efficiency, high accuracy, and precision, which can detect flaws and mutations in any functioning biomolecules like DNA, RNA, and protein.

Market Dynamics

Advancement in multiplexed diagnostics for various applications is expected to drive market growth.

Clinically significant immunosensors that are accurate, dependable, and economical are required for the early detection and surveillance of progressive diseases. Multiplexed sensing is a potential approach for the coming generation of diagnostics. With this method, numerous biomarkers can be simultaneously detected and quantified with much-improved reproducibility and reliability while needing less sample material and a shorter average analysis time for each biomarker than separate tests. For instance, one of the most frequently discussed multiplexing techniques is spatial multiplexing since it minimizes detection interferences and is compatible with most measurement techniques. Field-effect transistors are frequently used as the sensing mechanism for electrical measurements (FETs). A conductive or semiconductive channel makes up each transistor, and a particular antibody has altered this channel. The drain-source current is adjusted upon the binding of the relevant antigen to the sensing channel, and from this, the concentration of the target biomarker can be calculated. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

High costs associated with multiplexed diagnostics assay, lack of availability of skilled professionals, and Comparing multiplexed assay diagnostic tests to conventional diagnostic tests, there is a lack of clarity regarding reimbursement regulations among private and governmental players. Thus, from the above statements, the market is expected to get hampered in the forecast period.

Industry Analysis

The multiplexed diagnostics market provides in-depth analysis of the market based on various industry factors such as porter's five forces, supply chain analysis, reimbursement scenario, product innovation, pricing analysis, etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Rapid molecular testing for practical and prompt detection of SARS-CoV-2 infections is a challenge that could aid in managing the current pandemic and preventing further outbreaks. Lyophilized LAMP reagents are used in a multiplex and colorimetric RT-LAMP assay designed for the quick and sensitive detection of SARS-CoV-2. A set of gene targets found through genome-wide analysis of viruses inspired the creation of LAMP primers. A multiplex RT-LAMP assay was created using primer sets demonstrating the best features. As part of the analytical validation process, the limit of detection (LoD), intra- and inter-assay precision, and cross-reactivity with other respiratory pathogens were also evaluated. Therefore, it has increased the demand for multiplexed diagnostics assays.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Next-Generation Sequencing Assays segment is expected to hold the largest market share in multiplexed diagnostics market

The next-generation sequencing assays segment is expected to dominate in 2021. The segment is beneficial because it has improved low-frequency variant detection sensitivity, quick turnaround times for large sample quantities, extensive genome coverage, increased sample multiplexing capability, and simultaneous sequencing of hundreds to thousands of genes or gene regions. For instance, Illumina, Inc. is an American company that develops, manufactures, and markets integrated systems to analyze genetic variation and biological function. Moreover, large numbers of libraries are pooled and sequenced concurrently using Illumina multiplex sequencing during a single run. The traditional Sanger chain-termination technique differs significantly from Illumina NGS technology's operation. It uses massively parallel sequencing by synthesis (SBS) technology, which monitors the addition of tagged nucleotides as the DNA chain is duplicated. The amount of DNA sequencing data produced by next-generation sequencing is enormous, yet it is also less expensive and time-consuming than conventional Sanger sequencing. Depending on the instrument type and setup, Illumina sequencing systems can produce data output ranging from 300 kilobases to several terabases in a single run. Therefore, it has increased the demand for next-generation sequencing technology. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global multiplexed diagnostics market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cancer, rising consumer awareness, technological advancements, quick adoption of cutting-edge diagnostic techniques, a well-defined regulatory environment, sophisticated healthcare infrastructure and product launches and acquisitions by the key market players are some factors the market is expected to boost in the forecast period. For instance, In the United States, 1,752,735 new cancer cases were reported in 2019, while 599,589 people died from the disease. Four hundred thirty-nine new cases of cancer and 146 cancer-related deaths were reported for every 100,000 persons. In contrast, in the US, 1,806,590 new cancer cases and 606,520 cancer-related deaths are anticipated in 2020, or 4,950 new cases and more than 1,600 fatalities daily.

Moreover, A US-based firm called Chembio Diagnostic Systems Inc. is creating many multiplex diagnostic technologies for managing fevers. The tests are built on the business's Dual Path Platform (DPP), a patented technology that offers superior performance to conventional lateral flow technology and simultaneous antigen and antibody detection capabilities in a disposable, quick test package. Therefore, it has increased the adoption of multiplexed diagnostics assays. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the multiplexed diagnostics market are Luminex Corporation, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., Qiagen N.V., Siemens Healthineers, Agilent technologies, BioMerieux SA, F.Hoffmann-La Roche Ltd, Hologic, Inc., Illumina, Inc.

F. Hoffmann-La Roche Ltd:

Overview:

Hoffmann-La Roche Ltd is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. It is one of the largest biotech companies, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. It is a global leader in in-vitro and tissue-based cancer diagnostics and a frontrunner in diabetes management. Its personalized healthcare strategy aims to provide medicines and diagnostics that enable tangible improvements in patients' health, quality of life and survival. Moreover, Roche Molecular, one of four customer-focused areas of Roche Diagnostics Solutions, develops, manufactures and supplies a wide array of innovative molecular diagnostic products, tests, platforms and technologies used to identify and quantify DNA and RNA from different organisms.

Product Portfolio:

eSensor Technology: The eSensor Technology is based on competitive DNA hybridization and electrochemical detection principles. eSensor Technology is highly specific for the target biomarker and is not based on fluorescent or optical detection. As a result, diagnostic tests are less prone to sample contamination risk and do not require time-consuming washing and preparation steps.

The global multiplexed diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancement in multiplexed diagnostics for various applications is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High costs associated with multiplexed diagnostics assay is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Reagents & Consumables*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Instruments
  • 7.4. Others

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology Segment
  • 8.2. Low Density Multiplexed Assays*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Medium Density Multiplexed Assays
  • 8.4. High Density Multiplexed Assays
  • 8.5. Very High Density Multiplexed Assays
  • 8.6. Next-Generation Sequencing Assays
  • 8.7. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Disease Diagnostics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Molecular Diagnostics
  • 9.4. Drug Development
  • 9.5. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinical Laboratories
  • 10.4. Academic & Research Institutes
  • 10.5. Diagnostic Centers
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Luminex Corporation*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Thermo Fisher Scientific
  • 13.3. Bio-Rad Laboratories, Inc.
  • 13.4. Qiagen N.V.
  • 13.5. Siemens Healthineers
  • 13.6. Agilent technologies
  • 13.7. BioMerieux SA
  • 13.8. F.Hoffmann-La Roche Ltd
  • 13.9. Hologic, Inc.
  • 13.10. Illumina, Inc.

LIST NOT EXHAUSTIVE

14. Global Multiplexed Diagnostics Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us